Use of Saccharomyces cerevisiae erg4 mutants for expressing mammalian glucose transporters

US7244821B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Guenter Mueller · Pocking, DE
• Silke Dlugai · Düsseldorf, DE
• Doerthe Voss · Düsseldorf, DE
• Eckhard Boles · Dreieich, DE

Key dates

• Filing date: Sep 10, 2003
• Grant date: Jul 17, 2007
• Expiry date: Aug 30, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.